For the year ending 2025-12-31, XENE has $633,163K in assets. $51,403K in debts. $199,163K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 199,163 | |||
| Marketable securities (note 5) | 349,723 | |||
| Other receivables | 1,371 | |||
| Prepaid expenses and other current assets | 10,392 | |||
| Total current assets | 560,649 | |||
| Marketable securities, long-term (note 5) | 37,152 | |||
| Operating lease right-of-use asset, net (note 7) | 6,626 | |||
| Property, plant and equipment, net (note 6) | 8,721 | |||
| Deferred tax assets (note 14) | 12,864 | |||
| Prepaid expenses, long-term | 7,151 | |||
| Total assets | 633,163 | |||
| Accounts payable and accrued liabilities (note 8) | 40,260 | |||
| Operating lease liability (note 7) | 1,532 | |||
| Total current liabilities | 41,792 | |||
| Operating lease liability, long-term (note 7) | 6,412 | |||
| Other liabilities, long-term | 3,199 | |||
| Total liabilities | 51,403 | |||
| Common shares, without par value unlimited shares authorized issued and outstanding 80,010,790 (december 31, 2024 - 76,413,086) (note 9) | 1,598,571 | |||
| Additional paid-in capital | 228,234 | |||
| Accumulated deficit | -1,245,380 | |||
| Accumulated other comprehensive income (loss) | 335 | |||
| Total shareholders' equity | 581,760 | |||
| Total liabilities and shareholders equity | 633,163 | |||
Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. (XENE)